Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. The deal is potentially worth more than $500 million, including a $40 million upfront payment to Nabi and future milestone and royalty payments. Nabi shareholders voted in favor of the deal ...

AMSTERDAM (Reuters) - The Dutch government wants to sell 21 million unused H1N1 flu vaccine doses back to their manufacturers after they proved unnecessary and no other country wanted to buy them, the Health Ministry said on Saturday. A spokeswoman for the ministry said it had approached manufacturers GlaxoSmithKline and Novartis about buying back the doses. She added that it was ...

GlaxoSmithKline PLC could be facing liabilities up to $6 billion over personal injury lawsuits relating to its diabetes drug Avandia, UBS analysts said in a note made public on Friday. The UBS note, which comes a week after a highly critical report on the drug by the U.S. Senate Finance Committee, said the risk came from more than 13 ...

Nabi Biopharmaceuticals said Tuesday shareholders approved its option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. More than 73 percent of Nabi's outstanding shares were voted in favor of the transaction, and of the shares that were voted, more than 99 percent were in favor of the ...